Treatment of astrocytomas.
OBJECTIVE
Astrocytomas are the most common primary brain tumors. We will review recent developments in the understanding of the biology of these neoplasms and recent trials demonstrating promising improvements in the survival of patients with malignant gliomas.


RESULTS
Temozolomide along with radiation has become the standard of care for patients with newly diagnosed glioblastoma. Nonetheless, despite this advance in treatment, these tumors remain incurable. Biological markers and alternative treatment regimens will likely improve survival in patients with high-grade gliomas.


CONCLUSIONS
A recent study demonstrating the benefit of combined temozolomide and radiation provides a platform on which to build new treatment regimens. Further developments in the understanding of the biology of these tumors will permit specific interventions in selected patients that ultimately will improve outcomes.
Gonzalez
Javier
J
MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA.
Gilbert
Mark R
MR
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001254:Astrocytoma / Q000145:classification / Q000628:therapy*; D001932:Brain Neoplasms / Q000145:classification / Q000628:therapy*; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004358:Drug Therapy / Q000379:methods; D006801:Humans; D011878:Radiotherapy / Q000379:methods; D015398:Signal Transduction; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide